Acorda Therapeutics crashes 40% after patients die in drug trial
Advertisement
Advertisement
Advertisement
- Acorda Therapeutics, a drugmaker, plunged around 40% after patients died during the company's Parkinson's disease drug trial, according to Bloomberg's Natasha Rausch.
- Seven patients in the trial, which was in the final stages, developed a severe infection called sepsis, and five died.
- The company said it would stop adding new patients to the trial.
- It said it has no hypothesis yet for how the patients died, but four of the patients that developed sepsis also developed a condition called agranulocytosis, where white-blood cells disappear from the body, which can be linked to the drug.
- Shares were up 50% for the year before the drop on Wednesday.
- Read Bloomberg's full story here.
NOW WATCH: Why Nintendo is dominating like the old days
Advertisement
- Stock markets stage strong rebound after 4 days of slump; Sensex rallies 599 pts
- Sustainable Transportation Alternatives
- 10 Foods you should avoid eating when in stress
- 8 Lesser-known places to visit near Nainital
- World Liver Day 2024: 10 Foods that are necessary for a healthy liver